NSCLC is often associated with epidermal growth factor receptor (EGFR) overexpression, which occurs in 40%–80% of patients; therefore, EGFR-targeting therapies have been investigated [2]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.